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Abstract
Background:  Peripheral arterial disease (PAD) is a common disease associated with a
considerably increased risk of future cardiovascular events and most of these patients will die from
coronary artery disease (CAD). Screening for silent CAD has become an option with recent non-
invasive developments in CT (computed tomography)-angiography and MR (magnetic resonance)
stress testing. Screening in combination with more aggressive treatment may improve prognosis.
Therefore we propose to study whether a cardiac imaging algorithm, using non-invasive imaging
techniques followed by treatment will reduce the risk of cardiovascular disease in PAD patients free
from cardiac symptoms.
Design: The GROUND study is designed as a prospective, multi-center, randomized clinical trial.
Patients with peripheral arterial disease, but without symptomatic cardiac disease will be asked to
participate. All patients receive a proper risk factor management before randomization. Half of the
recruited patients will enter the 'control group' and only undergo CT calcium scoring. The other
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half of the recruited patients (index group) will undergo the non invasive cardiac imaging algorithm
followed by evidence-based treatment. First, patients are submitted to CT calcium scoring and CT
angiography. Patients with a left main (or equivalent) coronary artery stenosis of > 50% on CT will
be referred to a cardiologist without further imaging. All other patients in this group will undergo
dobutamine stress magnetic resonance (DSMR) testing. Patients with a DSMR positive for ischemia
will also be referred to a cardiologist. These patients are candidates for conventional coronary
angiography and cardiac interventions (coronary artery bypass grafting (CABG) or percutaneous
cardiac interventions (PCI)), if indicated. All participants of the trial will enter a 5 year follow up
period for the occurrence of cardiovascular events. Sequential interim analysis will take place.
Based on sample size calculations about 1200 patients are needed to detect a 24% reduction in
primary outcome.
Implications: The GROUND study will provide insight into the question whether non-invasive
cardiac imaging reduces the risk of cardiovascular events in patients with peripheral arterial disease,
but without symptoms of coronary artery disease.
Trial registration: Clinicaltrials.gov NCT00189111
Background
Peripheral arterial disease and coronary artery disease
Peripheral arterial disease (PAD) is the term used to refer
to lower-extremity arterial disease. It is a sign of systemic
atherosclerosis affecting millions of people, in particular
the elderly. Reports from the Framingham Heart Study
suggest that the prevalence of PAD has increased between
1970 and 2003 [1,2]. Estimates are that approximately
10% of individuals > 55 years have asymptomatic PAD
(defined as an ankle-brachial index (ABI) < 0.90) [3]. The
prevalence of so called intermittent claudication (IC) in
patients aged 55 to 74 years is approximately 4.6% [3] and
the prevalence of pain at rest and necrotic lesions (Fon-
taine stage IV) is approximately 1% [4]. Despite the rela-
tively benign prognosis for the affected limb, symptoms
of IC should be regarded as a sign of systemic atheroscle-
rosis and a high risk of cardiovascular events. In a review
on IC, Coffman et al. [5] described survival rates among
IC patients of approximately 70% to 80% after 5 years,
40% after 10 years, and 26% after 15 years. More recent
studies showed an overall 5-year-mortality rate of 19.2%
vs. 10% in controls [6] and 10-year-mortality rates of
61.7% among male and 33.3% among female patients
with IC, compared to 16.9% of men and 11.6% of women
without evidence of PAD [7]. The mean age of participants
in these studies was 67 and 66 years, respectively. Mortal-
ity due to coronary artery disease (CAD) after 5 years in a
study by Leng et al. was 5.5% vs. 2.6% in controls [6] and
after 10 years cardiac death occurred in 35.3% of men and
9.1% of women with IC, compared to 5.5% of men and
2.2 % of women without IC [7]. So not only do PAD
patients have two or three times the overall mortality, the
risk of cardiac death is even 4–6 times higher [7].
This increase in cardiovascular mortality is not surprising
since several studies showed a two or three times increase
in cardiovascular morbidity in PAD patients [6,8,9]. In
2003 Sonecha et al. published a study in which they
found CAD in 46% of IC patients, compared to 6% in
controls; 31% of claudicants even had 2-/3-vessel disease
[10]. Aronow et al. found a prevalence of CAD in PAD
patients of 58% [11]. Hertzer et al. described the results of
coronary angiography (CAG) in 1000 patients scheduled
for vascular surgery. In this group, 381 had complaints of
lower extremity ischemia, of whom 166 (44%) had no
cardiac complaints. CAG revealed the presence of CAD in
86% of these cardiac asymptomatic PAD patients [12].
Therefore, assessment of cardiac atherosclerotic abnor-
malities using non-invasive techniques followed by
appropriate treatment may help to improve survival in
patients with PAD but yet without cardiac symptoms.
Cardiac imaging with multi-detector CT and MRI
Since the discovery of selective coronary angiography
(CAG) by Sones in 1958, it has been the method of choice
for detection and follow-up of CAD. Several studies have
shown that diagnostic CAG has a morbidity of 2% and a
mortality of approximately 0.1% [13-15]. For screening
purposes non-invasive imaging would be much more
suitable. The rapid development of multi-detector com-
puted tomography (MDCT) has made it possible to image
the heart and its coronary arteries in a non-invasive way.
It is much faster than older scanners and images are
obtained with sub millimeter spatial resolution and high
temporal resolution. As a result of simultaneous recording
of an electrocardiogram (ECG) signal, several image
reconstructions are possible in different phases of the
heart cycle [16].
Several studies showed the high accuracy of MDCT to
detect clinically important coronary stenoses. [17-19] Not
only the costs and risk of complications are lower withTrials 2008, 9:49 http://www.trialsjournal.com/content/9/1/49
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MDCT than with CAG [13-15], this technique also has the
advantage of vessel wall visualization. Both the composi-
tion of the plaque and its impact on the vessel lumen can
be detected. A distinction can be made between lipid,
fibrous and calcified coronary plaques [20]. In recent
years it has become clear that plaque composition may be
a better risk-predictor for acute coronary events than sten-
osis grade. Rupture of so called vulnerable plaques
accounts for approximately 70% of sudden coronary
deaths[21]. Although the absolute risk of severely stenotic
plaques may be higher than the absolute risk of mildly
stenotic plaques, the number of plaques with mild sten-
oses overwhelmingly exceed the number of plaques with
severe stenoses [21].
Dobutamine stress cardiovascular magnetic resonance
imaging (DSMR) is used to identify wall motion abnor-
malities of the left ventricle indicative of myocardial
ischemia [22-26]. It has been shown to be an accurate and
safe diagnostic modality to assess myocardial ischemia
and viability in patients with proven or suspected CAD
[23-28]. A study by Nagel et al. showed that the presence
of myocardial ischemia can be detected more accurately
with DSMR than with dobutamine stress echocardiogra-
phy (DSE). Image quality of DSMR is higher and with MRI
sensitivity increased from 74.3% to 86.2% (P < 0.05) and
specificity increased from 69.8% to 85.7% (P < 0.05)
compared to echocardiography [23]. With the use of myo-
cardial tagging sensitivity can be increased up to 96%
[26]. In this study by Kuijpers et al. the cardiovascular
occurence-free survival rate was 98.2% after a negative
DSMR during a mean follow-up of 17.3 months. Further-
more, MRI allows optimal detection of dysfunctional, but
viable myocardium. This is of clinical importance since
revascularization of dysfunctional, but viable myocar-
dium may improve left ventricular function and thus
prognosis [29].
In patients with non-specific symptoms of coronary artery
disease DSMR can be used to assess risk levels for coronary
events with high accuracy. In a group of 100 patients sus-
pected of coronary ischemia Van Dijkman et al. found a
positive predictive value (PPV) of 98% and also a negative
predictive value (NPV) of 98% for ischemia with DSMR.
In this study the prevalence of ischemia was 43% [30]. In
another study by Hundley et al. a 97% cardiac event free
survival rate in 103 patients suspected of ischemia with a
negative DSMR was observed [25]. Patients with a nega-
tive DSMR without rest wall motion abnormalities
(RWMA) and without a history of CAD have an excellent
cardiac prognosis and can be excluded from further clini-
cal follow-up [31].
Compared to other non-invasive techniques, DSMR may
be a valuable adjunct for the assessment of patients with
(suspected) ischemic heart disease [32].
Treatment of silent coronary artery disease
According to the guidelines CABG or PCI may be consid-
ered as first line therapy in case of severe abnormalities in
the coronary artery tree, even in asymptomatic patients
[33]. Absence of cardiac symptoms should not be
regarded as a sign of a more benign process [34]. In addi-
tion, silent myocardial ischemia has been shown to
increase coronary artery disease risk and evidence indi-
cates that in certain groups of these patients CABG or PCI
treatment may reduce the risk. The results of the Asymp-
tomatic Cardiac Ischemia Pilot (ACIP) study indicate that
higher-risk patients with asymptomatic ischemia and clin-
ically important coronary artery abnormalities, who
undergo revascularization with CABG or PCI may have a
better outcome as compared to those only receiving med-
ical therapy [35]. Studies on the treatment of silent
ischemia are all conducted in small groups of patients
with coronary abnormalities [36]. In patients with left
main disease, the survival benefit of CABG compared to
medical therapy is 19.3 months at 10-year follow-up.
Therefore, the benefit of surgery over medical treatment
for patients with left main stenosis (> 50%) is little argued
[37].
Study objective
This prospective, randomized, controlled, multicenter
trial is designed to evaluate whether a cardiac imaging
algorithm using non-invasive imaging techniques fol-
lowed by evidence based treatment will reduce the risk of
cardiovascular disease in cardiac asymptomatic patients
with peripheral arterial disease. This imaging algorithm
consists of coronary calcium scoring, MDCT angiography,
and dobutamine stress MRI. Participants will be followed
up for a period of five years (figure 1). As a secondary
objective we will explore the role of coronary calcification
in this particular patient group.
Methods
Study group
The study group will consist of approximately 1200
patients with peripheral arterial disease without a history
of symptomatic cardiac disease. Patients are recruited
from the vascular surgery departments of the participating
centers (appendix 1). The study is in compliance with the
Helsinki Declaration and local ethics committees gave
their approval. Patients willing to participate will be asked
to sign the informed consent form. Patients are eligible if
they are 50 years or older and have peripheral arterial dis-
ease, at least stage Fontaine II, as diagnosed by the vascu-
lar surgeon. Patients will be considered not eligible for the
study if they meet one of the following exclusion criteria:
physician diagnosed history of symptomatic cardiac dis-
ease; cardiac rhythm other than sinus; unable to sustain a
breath-hold for 25 seconds; asthma; contra-indications to
MRI examination, such as vessel clips in the brain, metal
splinters in the eye, insulin pump or other electronicalTrials 2008, 9:49 http://www.trialsjournal.com/content/9/1/49
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devices that cannot be removed easily, metal implants,
port-a-cath catheter or claustrophobia; contra-indications
to iodinated contrast agent; severe arterial hypertension (>
220/120 mmHg); clinically important aortic stenosis;
unable to remain in supine position for at least 60 min-
utes; extreme obesity (BMI > 40 kg/m2); renal insuffi-
ciency (serum creatinine level exceeding 140 μmol/l);
severe physical deterioration due to concomitant disease;
language barrier; and contra-indications to dobutamine.
Baseline risk factors
At baseline, eligible patients complete a questionnaire on
current medication use, risk factors and quality of life.
Height, weight, blood pressure and ankle pressure for cal-
culation of the ankle-brachial index will be measured in
the outpatient clinic. Total cholesterol, high density lipo-
proteins (HDL), triglycerides, creatinine, homocysteine,
glucose and high sensitivity c-reactive protein will be
measured at the local laboratory. These measurements
were not standardized across the four different laborato-
ries. To prevent further progression of their present cardi-
ovascular disease all patients will be treated according to
the Dutch guidelines for treatment of atherosclerotic
peripheral arterial disease [38]. These guidelines state that
these patients should receive aspirin, a statin and antihy-
pertensive medication, if indicated. Patients also receive
proper advice regarding exercise, healthy diet and cessa-
tion of smoking.
MDCT imaging
All centers participating in the GROUND study are experi-
enced in making cardiac MDCT angiography scans and
use at least a 16-slice CT scanner. The patient preparation
will start with explanation of the procedure. The ECG
monitor is connected and sinus rhythm is monitored for
1 minute. Then the patient practices a 25 second breath-
hold. The MDCT calcium scoring examination will follow
a scout view. It will be done either prospectively ECG-trig-
gered or retrospectively gated according to the local hospi-
tal protocol. For the patients randomized to the imaging
arm of the study, calcium scoring will be followed by the
contrast enhanced retrospectively ECG-gated CT angiogra-
phy. An 18 G intravenous line is started. Patients who
have a heart rate over 60 bpm will be administered i.v.
beta-blockers (minimum of 5 mg metoprolol). Patients
will continue to receive beta-blockers until their heart
rates are below 60 bpm, or 20 mg has been administered.
Blood pressure will be monitored. The contrast volume
and infusion rate will be calculated individually depend-
ing on patient weight and scan duration and contrast con-
centration. Ten axial image datasets will be reconstructed
every 10% of the RR interval on the electrocardiogram.
Total examination time for CT calcium scoring will be
approximately 10 minutes and the total examination time
for CT calcium scoring and CT angiography, including
preparation of the patient, will be approximately 30 min-
utes. Total estimated radiation dose for the patient is
recorded.
MDCT Analysis
The cardiac MDCT data will be analyzed by the site inves-
tigator at the site. The reader will use the appropriate
workstation for all data analysis. The site investigator is
responsible for incidental abnormal findings in the data-
set.
The calcium scoring study will be evaluated using an
established analysis program (Heartbeat-CS, EBW, Philips
Medical Systems). Agatston, Mass and Volume scores will
be determined and recorded on case report forms. For the
MDCT angiography the site investigator will identify the
phase with the least amount of cardiac motion. This phase
is then loaded into the appropriate application. Depend-
ing on the coronary morphology and quality of the scan
several post processing techniques will be applied to
Flow Diagram of the GROUND Study Figure 1
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assess the coronary arteries. The dataset will be evaluated
in terms of contrast opacification, assessability, stenoses
and plaques. The proximal, medial and distal coronary
arteries and cranial, medial and caudal right ventricle are
evaluated for contrast opacification and image noise using
a 5-point scale (1 = non-diagnostic, 2 = limited diagnostic,
3 = acceptable, 4 = good, 5 = excellent).
The 15-segment tree from the American Heart Association
will be used for segment definition. Each segment will be
evaluated for assessability using a 5-point scale (1 = non-
diagnostic, 2 = limited diagnostic, 3 = acceptable, 4 =
good, 5 = excellent). For the segments that are not assess-
able (score 1 or 2) the reader will indicate why the seg-
ment cannot be evaluated according to the following
choices: (0) anatomical reason, (1) respiratory motion,
(2) cardiac motion, (3) arrhythmia, (4) calcium, (5) ves-
sel size (small caliber), (6) poor opacification, (7) streak
artifacts, (8) scan range, (9) noise, (10) technical failure.
Any luminal narrowing greater than 30% will be visual-
ized from the curved MPR and will be quantified accord-
ing to a 4-point scale: (1) 30–50%, (2) 50–70%, (3) 70–
99% and (4) 100%. The type of visualized plaque will be
indicated as soft, calcified or mixed. All scan data will be
transferred to the core laboratory for a second reading of
the data. Inter- and intra-observer variability will be deter-
mined.
DSMR imaging
Patients randomized to the imaging group will under go
dobutamine stress MRI within three weeks of the MDCT
angiography. All beta-blocking medication will be
stopped 4 days prior to the examination [26]. After
instructions by the technician, the patient is positioned on
the scanning table and an intravenous access will be estab-
lished through an antecubital vein. ECG leads, a phased-
array surface coil covering the heart, and a brachial blood
pressure cuff are applied. During the procedure, a single-
lead ECG will be continuously monitored. Systolic blood
pressure, diastolic blood pressure and heart rate will be
recorded at baseline and every three minutes throughout
the procedure.
Baseline imaging will consist of acquiring three short-axis
cine images (basal (1.5 cm below mitral valves), mid-ven-
tricular and apical) and one vertical long-axis cine image.
Cine tagged images are made in the three short axis
planes.
During the DSMR dobutamine will be infused intrave-
nously using a digital pump injector situated outside the
scanner room. The dose will be increased to 10, 20, 30
and 40 μg/kg/min with a six minutes time interval. In case
of rest wall motion abnormalities (RWMA), infusion will
be started at 5 μg/kg/min. Image acquisition will start
three minutes after each dose increment. Imaging will
consist of acquiring three short-axis cine images (basal,
mid-ventricular and apical) and one vertical long axis
with and without myocardial tagging. Criteria for ending
the examination are (1) development of new or worsen-
ing wall motion abnormalities (NWMA) in more than 1
myocardial segment, (2) fall of systolic blood-pressure of
> 40 mmHg, (3) marked hypertension > 240/120 mmHg,
(4) severe chest pain, (5) complex cardiac arrhythmia's
and (6) intolerable side effects of dobutamine.
Both a radiologist (or a trained radiology resident) and a
cardiologist (or a trained cardiology resident) will be
present in the MR suite to monitor the condition of the
patient and to directly evaluate the images. The target
heart rate rule is not applied. Studies have shown that this
is a safe and effective method [26,28,31].
All participating centers have experience in dobutamine
stress testing. Although side effects are rare, a protocol to
remove the patient from the scanner room in case of an
emergency is practiced regularly. Total examination time
for a DSMR study, including preparation of the patient,
will be approximately 50 minutes.
DSMR Analysis
The DSMR data will be analyzed by the site investigator at
the site. The reader will use the appropriate workstation
for all data analysis. For image interpretation multiple
cine loop display will be used displaying at least three dif-
ferent stress levels for each slice simultaneously. Per seg-
ment wall motion will be graded using a 4-point scale
according to the guidelines of the American Society of
Echocardiography (1 = normal or hyperkinesia, 2 = hypo-
kinesia, 3 = akinesia and 4 = dyskinesia). The sum of
points is divided by the number of analyzed segments and
yields the wall motion score [39]. Normal contraction
results in a wall motion score of 1, a higher score is indic-
ative of wall motion abnormalities. During dobutamine
stress with increasing doses, a lack of increase in either
wall motion or systolic wall thickening, a reduction of
both or significant changes in the rotational pattern of left
ventricular myocardium ('tethering') are indicative of
pathological findings. Myocardial ischemia will be
defined as an induced WMA in at least two segments at
consecutive planes of the left ventricle. RWMA will be
defined as WMA in one or more segments at baseline. If
RWMA's are present, which improve during low-dose
dobutamine stress, but worsen during peak-stress, this
will be considered diagnostic of inducible myocardial
ischemia. If RWMA's are present, which do not improve
with low-dose dobutamine, this will not be considered
diagnostic of inducible ischemia. Also ejection fraction,
end-diastolic volume and end-systolic volume will be
documented. All scan data will be transferred to the coreTrials 2008, 9:49 http://www.trialsjournal.com/content/9/1/49
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laboratory for a second reading of the data. Inter- and
intra-observer variability will be determined.
Randomization
Randomization will be performed per hospital to ensure
an equal distribution of groups of patients within hospi-
tals. Directly after the patient gives informed consent, he
or she is randomized with the use of the randomization
module at the GROUND website. Only the data manage-
ment center is aware of block size. This way half of the
patients will be randomized for the imaging-with-treat-
ment algorithm (groups B, C and D, figure 1), the other
half of the patients (group A) undergoes only CT calcium
scoring and enters follow-up. Patients randomized for the
treatment groups (groups B, C and D, figure 1) will be
scheduled for MDCT angiography. If a stenosis of the left
main coronary artery (LM) (or equivalent) of more than
50% is observed on the CTA of a patient in the imaging-
with-treatment group, he/she will be referred to a cardiol-
ogist for further diagnosis and treatment (group B, figure
1). A stenosis in the proximal left anterior descending cor-
onary artery (LAD) in combination with a stenosis in the
proximal circumflex coronary artery (LCX) is considered
equivalent to a LM stenosis. All other patients in this
group will undergo DSMR testing (groups C and D).
Patients with a DSMR positive for ischemia are referred to
a cardiologist for further diagnosis and treatment (group
C). Further diagnostics and treatment will be left up to the
cardiologist.
Data collection
Study data, including detailed data on diagnostic and
therapeutic measures taken by the cardiologist, will be
collected on case report forms (CRF's) and submitted on
line to the data management center, located at the Julius
Center for Health Sciences and Primary Care http://
www.juliuscenter.nl, where all forms are reviewed for
completeness. CRF's are available on the GROUND web-
site. Data will end up in a dedicated database.
End points and follow-up
All patients will be asked to fill out a short follow up form
every half year for a total period of five years. The occur-
rences of events are recorded. The quality of life assess-
ment is based on the SF36 questionnaire and repeated
after 12, 30, 48, and 60 months. This questionnaire has
been validated in the Dutch population [40]. Endpoints
of the GROUND study are in concordance with the
SMART [41] study endpoints.
The term 'end points' is used to describe death, cardiovas-
cular complications, and interventions. Apart from death
the occurrence of an endpoint does not imply that the fol-
low-up will be ended. Endpoints in the GROUND study
are summarized as MACE: Major Adverse Clinical Events.
Primary outcome is a composite endpoint comprising
fatal and non-fatal myocardial infarction and stroke, and
vascular death (death due to vascular disease). Secondary
end points are: fatal and non-fatal myocardial infarction;
fatal and non-fatal stroke; vascular interventions; amputa-
tion; aortic rupture; end stage renal failure extra cranial
hemorrhage; complications of CABG or PCI and all cause
mortality.
Reported endpoints are classified by the Endpoint Com-
mittee, which is unaware of the randomization allocation.
Clinical information (letters of discharge) is obtained
from the treating specialist or general practitioner. All
reported endpoints enter an endpoint verification proce-
dure. Copies of discharge records are sent to the members
of the Endpoint Committee. The members of the End-
point Committee do not share the information between
each other, but classify the events independently. Only if
discharge records are inconclusive further medical infor-
mation is obtained (results from laboratory findings, copy
of the ECG, copies of imaging reports). The classifications
are compared. If two members do not agree the endpoint
will be discussed with the blinded research physicians of
the GROUND study group. They will decide or consult an
extra physician, whose judgment is regarded as final.
Sample size considerations
The sample size is determined by the estimated risk in the
group of patients randomized to usual care (control
group, A, figure 1) and the risk observed in the groups that
undergo cardiac imaging followed by subsequent treat-
ment by a cardiologist as outlined in the protocol (groups
B to D). Based on earlier studies in the Netherlands the 5-
year-risk in the control group is assumed 24%[42]. The 5
year risk of cardiovascular morbidity and mortality
among the IC patients that undergo cardiac imaging and
subsequent treatment is based on the sum of I) the risk
observed in those with stenosis in the main left coronary
artery (group B, figure 1) plus II) the risk observed in
those with limited vessel disease but no ischemia during
the dobutamine stress test (group D) plus III) the risk
observed in those with limited coronary vessel disease but
with ischemia during the dobutamine stress test (group
C).
The prevalence of these subgroups B to D in the arm of
cardiac imaging and subsequent treatment is estimated to
be 8% for B; 70% for D and 22% for C. Using the litera-
ture we have estimated the risk of cardiovascular morbid-
ity and mortality for these groups of patients belonging to
category B to D.
The 5-year risk of cardiovascular morbidity and mortality
in these subgroups is 66% for those with stenosis of the
left main coronary artery[41] (group B), 32.8% for thoseTrials 2008, 9:49 http://www.trialsjournal.com/content/9/1/49
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with cardiac ischemia during the stress test (group C) and
16.4% for those without cardiac ischemia (group D).
The estimates for patients in categories C and D are based
on the assumption that those with cardiac ischemia have
a doubling of risk compared with those without cardiac
ischemia and that the risk of all groups combined should
add up to 24%.
The effects of interventions performed by the cardiologist
on the risk observed in PAD patients who undergo cardiac
imaging are based on published international data from
the ACC and AHA guidelines. These effects are for the two
appropriate subgroups: 70% reduction in 5-year event
rate using reperfusion therapy (PCI/CABG) for group B
and 40% reduction in 5-year event rate using reperfusion
therapy (PCI/CABG) for group C. Patients without cardiac
ischemia (group D) will receive no treatment.
Based on these estimates, the 5-year risk of cardiovascular
morbidity and mortality will be 17.4 % in the interven-
tion group (the combined risk for groups B and C; 70%
event reduction in the group with a risk of 66% applying
to 8% of the population; 40% event reduction in the
group of patients with a risk of 32.8% applying to 22% of
patients), reflecting an estimated relative reduction in car-
diovascular morbidity and mortality of 24%.
The total number of patients randomized to achieve this
goal, with a two-sided alpha of 0.05 and 80% power will
be 1222. For this calculation we used dedicated software
('Power', dr. P.G.H. Mulder, Erasmus Medical Center, Rot-
terdam, the Netherlands). A study of this size has a statis-
tical power of 80% at a two-sided alpha level of 0.05. The
reason for using interim analysis [43] is that on average
fewer patients are needed in the study when the expected
difference in the primary outcome variable is real or when
no difference can be expected anymore, therefore increas-
ing efficiency. Sequential analyses are performed on sur-
vival outcome variables according to the double
triangular test as described by Whitehead [44] and imple-
mented in the computer program PEST version 4 [45]. The
sequential (interim) analyses will be performed every
three months by an independent data safety monitoring
board (DSMB).
Statistical analysis
The analyses will be performed using the intention-to-
treat principle. To assess whether intervention is related to
a reduced risk of events we will use a chi-square analysis
comparing the observed absolute risks across treatment
groups. In addition, treatment efficacy will be assessed
using a Cox regression model and expressed as a hazard
ratio with corresponding 95 % confidence intervals. Since
this is a randomized controlled trial, no adjustments will
be made, although centers may be added. Associations
will be considered significant at p < 0.05. All statistical
tests will be 2 sided. For statistical analyses we will use
SPSS (SPSS for Windows, Chicago, Ill, SPSS Inc.).
Conclusion
Peripheral arterial disease is a common disease among
elderly persons and is associated with a very high risk of
cardiovascular events. In this study patients with periph-
eral arterial disease, but without cardiac symptoms, are
randomized to an imaging arm consisting of multi-detec-
tor CT angiography of the coronary arteries and dob-
utamine stress MRI or to a control group in which case
only a coronary calcium CT scan will be performed at
baseline. In case of a positive finding in the imaging arm,
patients are referred to a cardiologist who will take appro-
priate action. All participating patients will enter a 5-year
follow-up for the occurrence of cardiovascular events. To
the best of our knowledge GROUND is the first large trial
designed to assess the value of multi-detector CT and MRI
stress testing in reducing the morbidity and mortality of
patients with peripheral arterial disease but yet without
cardiac symptoms. At the time of writing this manuscript
all centers are actively enrolling patients. The first patient
enrolled in January 2005. The number of included
patients is currently 228.
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Appendix
Participating Centers
The following hospitals in the Netherlands have agreed to
participate in the GROUND-study: University Medical
Center Groningen; University Medical Center Utrecht; St.
Antonius Hospital Nieuwegein; Meander Medical Center,
Amersfoort.
Executive Committee
The Executive Committee is responsible for the design of
the GROUND study. It will coordinate and direct the
study to ensure its overall success and decide on practical
issues concerning the study. It will act upon recommenda-
tions of the Data Safety and Monitoring Board regarding
continuation of the study.Trials 2008, 9:49 http://www.trialsjournal.com/content/9/1/49
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Members of the executive committee are:
Prof. W.P.Th.M. Mali, MD, PhD, University Medical
Center Utrecht, responsible for the trial coordination
Prof. M. Oudkerk, MD, PhD, University Medical Centerl
Groningen, responsible for the radiological coordination
Prof. F. Zijlstra, MD, PhD, University Hospital Groningen,
responsible for the cardiological coordination
Dr. M.L. Bots, MD, PhD, University Medical Center
Utrecht (Julius Center) responsible for the epidemiologi-
cal coordination (project management, general data base
management and statistical analyses)
Steering Committee
The steering committee consists of radiologists, cardiolo-
gists, epidemiologists, vascular surgeons and researchers
of the participating centers. The Steering Committee will
perform the actual imaging procedures of the study. Mem-
bers will inform the Executive Committee on the progress
of the study regularly. The steering committee and the
executive committee will meet twice annually.
Members of the steering committee are: Mathias Prokop,
MD, PhD; Pieter A. Doevendans, MD, PhD; Annemarieke
Rutten, MD; Alexander M. de Vos, MD; Frans Moll, MD,
PhD; Evert-Jan Vonken, MD, PhD; Maarten-Jan M.
Cramer, MD, PhD; Birgitta K. Velthuis, MD, PhD (Univer-
sity Medical Center Utrecht); Hester J. van der Zaag, MD;
R.A. Tio, MD, PhD; T.P. Willems, MD, PhD; P.M. van Ooi-
jen, PhD; R. Vliegenthart, MD, PhD (University Medical
Center Groningen); Benno J. Rensing, MD, PhD; H.
Wouter van Es, MD, PhD; H.D. van de Pavoordt, MD,
PhD (St. Antonius Hospital Nieuwegein); Arend Mosterd,
MD, PhD; Ben G. Heggelman, MD; Robert A. Buiskool,
MD; Albert J. Mackaay, MD, PhD (Meander Medical
Center Amersfoort).
Endpoint Committee
The Endpoint Committee will systematically evaluate sus-
pected endpoints. Members are: F. Zijlstra, MD, PhD (car-
diologist); B. Rensing, MD, PhD (cardiologist); A.
Mosterd, MD, PhD (cardiologist); J. de Keyser, MD, PhD;
W.J. Schonewille, MD (neurologist); T.W.M. Raaijmakers,
MD, PhD (neurologist); M.L. Bots, MD (epidemiologist),
PhD; A. Rutten, MD (radiologist in training); A.M. de Vos,
MD (cardiologist in training).
Data Safety and Monitoring Board
The data safety and monitoring board performs statistical
analyses of un-blinded interim data and formulates rec-
ommendations for the Steering Committee on the contin-
uation of the trial. The DSMB may also offer unsolicited
recommendations on the continuation of the trial, for
example after publication of results of similar trials. Every
three months the chair of the DSMB will be provided an
interim dataset to perform sequential analyses. When
appropriate, given the results from the interim analysis,
the chair will call for a meeting with the other DSMB
members. Members of the Data Safety and Monitoring
Board are: Ingeborg van der Tweel, PhD (statistician);
Maarten-Jan M. Cramer, MD, PhD (cardiologist); Hester J.
van der Zaag, MD, PhD (epidemiologist); Diederick E.
Grobbee, MD, PhD (epidemiologist).
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